Advanced search
Publication Cover
The American Journal of Drug and Alcohol Abuse
Encompassing All Addictive Disorders
Volume 46, 2020 - Issue 3
Submit an article Journal homepage
647
Views
7
CrossRef citations to date
0
Altmetric
Methods in Addiction Research

A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder

Mohammad Sibaia Department of Psychology, University of Detroit Mercy, Detroit, MI, USAView further author information
,
Kaitlyn Mishlenb Division on Substance Use Disorders New York State Psychiatric Institute, New York, NY, USAView further author information
,
Edward V. Nunesb Division on Substance Use Disorders New York State Psychiatric Institute, New York, NY, USA;c Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USAView further author information
,
Frances R. Levinb Division on Substance Use Disorders New York State Psychiatric Institute, New York, NY, USA;c Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USAView further author information
,
John J. Marianib Division on Substance Use Disorders New York State Psychiatric Institute, New York, NY, USA;c Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USAView further author information
&
Adam Bisagab Division on Substance Use Disorders New York State Psychiatric Institute, New York, NY, USA;c Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4243-6462View further author information
ORCID Icon
Pages 289-296 | Received 01 Aug 2019, Accepted 27 Nov 2019, Published online: 20 Dec 2019

References

  • Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506–13. doi:10.1016/S0140-6736(11)60358-9.
  • Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2019;176:129–37. doi:10.1176/appi.ajp.2018.17070732.
  • Tanum L, Solli KK, Latif ZE, Benth JS, Opheim A, Sharma-Haase K, Krajci P, Kunoe N. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74:1197–205. doi:10.1001/jamapsychiatry.2017.3206.
  • Lee JD, Nunes EV Jr., Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309–18. doi:10.1016/S0140-6736(17)32812-X.
  • Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the national institute on drug abuse clinical trials network. Addiction. 2005;100:1090–100. doi:10.1111/add.2005.100.issue-8.
  • Day E, Strang J. Outpatient versus inpatient opioid detoxification: a randomized controlled trial. J Subst Abuse Treat. 2011;40:56–66. doi:10.1016/j.jsat.2010.08.007.
  • SAMHSA. National Survey of Substance Abuse Treatment Services (N-SSATS): 2016. In: Data on substance abuse treatment facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.
  • Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, Levin FR, Dakwar E, Mariani JJ, Nunes EV. Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry. 2017;174:459–67. doi:10.1176/appi.ajp.2016.16050548.
  • Umbricht A, Montoya ID, Hoover DR, Demuth KL, Chiang CT, Preston KL. Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend. 1999;56:181–90. doi:10.1016/S0376-8716(99)00033-2.
  • Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35:253–59. doi:10.1080/02791072.2003.10400007.
  • Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293–308. doi:10.3109/00952998709001515.
  • Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported ethanol consumption. In: Allen JP, Litten RZ, editors. Measuring alcohol consumption: psychosocial and biological methods. Totowa, NJ: Humana Press; 1992. p. 41–72.
  • Mannelli P, Wu LT, Peindl KS, Swartz MS, Woody GE. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend. 2014;138:83–88. doi:10.1016/j.drugalcdep.2014.02.002.
  • Bisaga A, Mannelli P, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Drug Alcohol Depend. 2018;187:171–78. doi:10.1016/j.drugalcdep.2018.02.023.
  • Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32:503–17. doi:10.1080/00952990600918973.
  • Bisaga A What should clinicians do as fentanyl replaces heroin? Addiction 2019. doi:10.1111/add.14522
  • Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017;174:738–47. doi:10.1176/appi.ajp.2016.16070792.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.